Sobi Announces Positive Phase 3 REDUCE-2 Data for Pozdeutinurad
Sobi presented late-breaking data from the pivotal Phase 3 REDUCE-2 study of pozdeutinurad, demonstrating durable serum urate reductions in patients with gout.
Stocks · News reference
Sobi Raises Full-Year 2026 Revenue Growth Guidance
Swedish Orphan Biovitrum AB (Sobi) has increased its revenue growth guidance for the 2026 fiscal year.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sobi Reports Q3 2026 Financial Results
Swedish Orphan Biovitrum AB (Sobi) released its third-quarter 2026 financial report, highlighting strong growth momentum for the company.